Welcome!

News Feed Item

Preclinical Investigation Shows Ground-Breaking Results on Human Infections

RHEINBREITBACH, Germany, November 14, 2012 /PRNewswire/ --

Synthetic human-milk-oligosaccharides reduce the risk of infections caused by hazardous pathogens

Human-milk-oligosaccharides, an important component of human mother's milk, play a fundamental role in the protection of infants against viral and bacterial infection. Preclinical studies carried out by Jennewein Biotechnologie GmbH have now shown for the first time that synthetically produced functional sugars protect humans from infectious diseases. The investigations were conducted in collaboration with the University Children's Hospital Mannheim of Heidelberg University (GER).

In collaboration with the University Children's Hospital Mannheim of Heidelberg University, Jennewein Biotechnologie GmbH carried out extensive preclinical research to demonstrate for the first time that synthetic human-milk-oligosaccharides achieve the same protective effects as natural sugars in human breast milk. The study focused on the human-milk-oligosaccharides 2'-Fucosyllactose and 3-Fucosyllactose, which are present in human breast milk at levels of up to 3.5 grams per liter and are by far the most abundant human-milk-oligosaccharides.

The researchers at Mannheim (GER) tested the sugars on human cells using various pathogens. The results demonstrate a clear protective effect, i.e. the synthetic human-milk-oligosaccharides produced by Jennewein Biotechnologie GmbH successfully bind prevalent diarrhea causing pathogens such as Campylobacter jejuni, Escherichia coli and particular Salmonella species. Furthermore, the now available results reveal that these saccharides effectively inhibit the pneumonia causing pathogen Pseudomonas aeruginosa, which is together with E. coli and Staphylococcus aureus the most common pathogen causing nosocomial infections. Moreover, Pseudomonas aeruginosa infections can cause severe, life-threatening infections in patients with underlying immunodeficiency.

Human-milk-oligosaccharides not only inhibit gastrointestinal pathogens directly, they also provide at least two further major benefits. First, they have a prebiotic or bifidogenic effect, encouraging the growth of bifidobacteria that improve digestion and suppress pathogens to maintain a healthy microbiome. Second, up to 1% of these saccharides are absorbed into the blood, where they provide a systemic protection such as reducing the risk of infection of organs such as the lungs and meninges, for example. Although there is abundant evidence for the benefits of human-milk-oligosaccharides further research is required to understand the underlying mechanisms. Jennewein Biotechnologie GmbH has taken the lead in this research and is committed to the development of innovative products based on synthetic human-milk-oligosaccharides to reduce infection rates in infants and adults.

As emphasized Prof. Dr. Schroten, Director of the University Children's Hospital Mannheim of Heidelberg University, " this study represents asignificant milestone in the development of novel and effective non-interventional strategies to reduce the risk of human infections by pathogenic bacteria. In consideration of the continued growth of the world population and the increasing number of multidrug-resistant bacteria, this represents one of the key challenges of the 21st century."

The protective mechanism of human-milk-oligosaccharides

Mother's milk is seen as the "gold standard" for infant nutrition during the first few months of human life, not only reflecting the optimal balance of nutrients but also because of its ingredients with specific biological functions. Human-milk-oligosaccharides are the third most abundant solid component of breast milk, after lactose and fat which primarily serve as energy source. These human-milk-oligosaccharides are highly complex sugar molecules which are human specific and therefore can only be found in nature in this composition in human mother's milk.

Many scientific studies have shown that human-milk-oligosaccharides reduce the risk of infection by pathogens and have no adverse effects in humans. Soluble human-milk-oligosaccharides imitate sugar molecules that are found on the surface of all human cells to facilitate cell-to-cell communication. More than 70% of human pathogens - virus and bacteria - use these cell-surface sugar molecules to attach to, enter and infect cells. Thus, soluble human-milk-oligosaccharides in the gastrointestinal tract and in the blood act as decoys to prevent pathogens interacting with cells. Human pathogens will connect to these soluble saccharides "assuming" they connect to a host cell. The binding between pathogens and sugar molecules is irreversible and pathogens have no possibility to become resistant to soluble human-milk-oligosaccharides because they need to interact with the same molecules on the cell surface. Therefore, pathogens that do not bind to these sugars would be unable to bind to the cell surface either, and would lose their virulence.

Because human-milk-oligosaccharides have a specific role in the elimination of pathogens they are not used by human cells as an energy source. However, they retain the organoleptic properties of other sugars, i.e. they are soluble and sweet. This means that human-milk-oligosaccharides could be added to the diet in place of sucrose, for example, acting as sweeteners with no calorific value but also providing prebiotic benefits and protecting against infection.

Multiple applications for Fucosyllactose in human nutrition

The synthetic human-milk-oliogsacchrides produced by Jennewein Biotechnologie GmbH are presented as white, crystalline powders similar to sucrose, making them ideal as additives for use by the food processing industry to increase the health-promoting characteristics of innovative food products. In specialized areas, Jennewein Biotechnologie GmbH already cooperates with Pfizer Nutrition, one of the leading international infant food manufacturers. However, there are many other potential applications outside the field of infant nutrition, ranging from dairy products, breakfast cereals and beverages providing health benefits to special nutrition programs for professionals facing a high risk of infection, dietary supplements for travelers in disease-endemic areas, special diets for immunocompromized hospital patients to prevent nosocomial infections and therapeutic nutrition used to improve patients' clinical outcomes and quality of life.

About Jennewein Biotechnologie GmbH

Jennewein Biotechnologie GmbH is active in the field of industrial biotechnology and specializes in the production of complex sugar molecules using bio-organic synthesis. The main focus of the company is the production of ingredients for the food, personal care and pharmaceutical industries. Jennewein Biotechnology also produces molecules for research and development, as well as for diagnostics.

Jennewein Biotechnologie GmbH is a family-owned company, founded in 2005 with its headquarters in Rheinbreitbach (Rhineland-Palatinate, Germany). The company cooperates in research and development with leading universities and research institutes. Jennewein Biotechnologie GmbH received the Pionier-Geist award in 2007 from the Rhineland-Palatinate Ministry of Economics. The Federal Ministry of Education and Research supports Jennewein Biotechnologie GmbH in its research and development activities in the field of human-milk-oligosaccharides.

Further information

Further information about Jennewein Biotechnology GmbH, its products and graphical material can be obtained at http://www.jennewein-biotech.de or by writing to:  

Jennewein Biotechnologie GmbH
Maarweg 32
D-53619 Rheinbreitbach
Germany
Tel.:  +49-(0)2224-989-4502
Fax.:  +49-(0)2224-988-0854
EMail: [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...